SAFC Pharma(R) Announces Completion of $12M Contract Manufacturing Facility Expansion in Carlsbad, Calif.

Featured In: Supplier News

By Sigma-Aldrich Corporation Friday, October 16, 2024

Loading...

ST. LOUIS, Oct 13, 2024 /PRNewswire-FirstCall via COMTEX News Network/ -- SAFC Pharma(R), a business segment of SAFC(R), a member of the Sigma-Aldrich(R) Group (Nasdaq: SIAL), today announced the completion of an addition to its Carlsbad, Calif., facility that expands the Company's contract manufacturing services for its late phase and commercial clients. The $12 million project includes the addition of two fully segregated state-of-the-art viral product manufacturing suites, built to employ the latest in disposable bioreactor technologies, expanding SAFC Pharma's biologics, viral vaccines and gene therapy manufacturing to commercial-scale quantities.

SAFC Pharma's Carlsbad site specializes in the process development and manufacturing of viral vaccines and viral therapeutics, including a full menu of support services, from preclinical process and analytical development to final fill/finish and commercial bulk drug supplies. The new expansion, designed for multi-lot campaigns, includes dedicated cell expansion, bioreactor production, purification and cleanroom suites. Adding 8,000 sq. ft. of manufacturing space to the existing 44,000 sq. ft. site, the addition enables both 100-liter batch production in stirred tank bioreactors and 1,000-liter batch manufacturing in disposable bioreactors, and is Biosafety Level 2 compliant, allowing manipulation of human pathogens. Designed from the outset as a containment facility, the expansion space allows clients to secure a dedicated suite of cleanrooms for larger scale manufacturing.

"We are delighted to announce this expansion of our capabilities at our Carlsbad facility, particularly when the economic environment has been so challenging," commented David Feldker, Vice President SAFC Pharma. "We expect to see a great deal of value in the biologics and viral manufacturing marketplace in the next three to five years generated by two main customer types - those with late clinical phase opportunities but without any in-house manufacturing capability and those with late clinical phase opportunities that have some manufacturing capabilities but may be seeking an additional 'safety net' or wish to avoid additional capital expansion until their technology and drug has proven itself. By adding and extending our capabilities at Carlsbad, we are providing customers with an attractive, clear pathway that adds value and supports secure, successful product launches."

"The expansion at our Carlsbad campus underlines SAFC's strategy to continue to invest in building world class capabilities that serve and enhance our leadership in important emerging new technologies such as niche biologics production and viral manufacturing - areas where we see great potential and traction," added SAFC President Gilles Cottier. "Our investment in large capacity manufacturing, our financial stability, experience and quality systems differentiates us in the market and enhances our abilities to securely support our customers all the way to successful product launch."

Facility validation studies are currently underway, with an expected start of cGMP manufacturing operations by the end of December 2009. The site added numerous utility support systems to allow for continuous operation and will now utilize its new Water For Injection (WFI) system. The Company has enjoyed a close relationship with a number of clients developing an exciting array of cancer therapeutics, gene therapies and mammalian and insect cell-based viral vaccines.

SAFC has announced worldwide investments totalling $90 million in the past two years to expand capacity for active pharmaceutical ingredients (API) production and biologic drug products. These investments build on the Company's strengths in complex emerging technologies such as high potency manufacturing and viral vaccines manufacturing, further expanding its capabilities to serve customers in these growing areas. The expansion in Carlsbad follows the acquisition in 2007 of Molecular Medicine BioServices, Inc.

About SAFC(R): SAFC is the custom manufacturing and services group within Sigma-Aldrich that focuses on high-purity inorganics for high technology applications, cell culture products and services for biopharmaceutical manufacturing, biochemical production and the manufacturing of complex, multi-step organic synthesis of APIs and key intermediates. SAFC has manufacturing facilities around the world dedicated to providing manufacturing services for companies requiring a reliable partner to produce their custom manufactured materials. SAFC has four focus areas - SAFC Pharma(R), SAFC Supply Solutions(R), SAFC Biosciences(R), and SAFC Hitech(R) - and had annual sales of over $600 million in 2008. SAFC is one of the world's 10 largest fine chemical businesses. For more information about SAFC, visit www.safcglobal.com.

About SAFC Pharma(R): SAFC Pharma is a complete pipeline partner for the development and cGMP custom manufacturing of complex small-molecule APIs and biologic drug products. It combines world-class project management and chemistry support for all stages of the drug discovery and development process from research and discovery, through pre-clinical and clinical development to commercialization, with a focus on reducing the drug development time-line. SAFC has the widest range of raw materials, highly qualified and experienced staff, state-of-the-art facilities and an integrated portfolio of services, including full analytical and regulatory support and is a leader in emerging technologies, including high-potency APIs, solid-state chemistry, viral products and chemical-biologic API conjugates. For more information visit www.safcpharma.com.

SOURCE

Join the Discussion
Rate Article: Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Research Exchange

Handle With Care

Aug 26

Researchers face the dual challenges of difficult to handle and hard to maintain stem cells.

Six Tips for More Successful Cell Cultures

Aug 18

For those who perform cell culture experiments, it pays to be meticulous. Even seemingly minor handling techniques and lab equipment features can make a difference in achieving success.

Rapid Generation of Assay-ready Serial Dilution Plates Using Two-stage Low Volume Pipetting

Jul 22

Researchers see the benefits of streamlining accurate serial dilution of stock solutions of compounds. By Joby Jenkins, TTP LabTech As the cost of drug development escalates there is a growing requirement to accelerate the R&D cycle and eliminate unwanted off-target drug effects earlier.

Imaging Through the Pipeline

Jun 15

The evolution of live animal imaging technology has helped researchers get a better picture of the drug research process, from target identification to pharmacokinetic studies.

The Future of the FDA: Operating in an Electronic World

Oct 12

Acording to an Axendia reseach study, the FDA is currently shifting its organizational and technology infrastructures to facilitate electronic interactions with the companies it regulates.

Tissue Microarrays - Opening up new opportunities in the Therapeutics sector

Oct 12

Tissue Microarray has become a pivotal cog in the wheel for high throughput studies and is an integral part in the validation process for screening results from discovery platforms for expression studies using various approaches.

Translational Informatics for Systems Biology

Oct 12

A study in which IO Informatics' Sentient software has been applied to integrating and linking a customer's multiple data streams.

De Novo Formula Generation with Sub-ppm Confidence

Oct 12

Novel technology embodied in the micrOTOF allows precise measurement of both accurate mass and True Isotopic Pattern (TIP) over a wide dynamic range, allowing for the implementation of an open access system.

ADP-Glo™: An Ideal Approach to Monitor the Activity of Protein Kinases and Beyond

Oct 16

Because of its versatility (alltypesofsubstrates), robustness (Z’>0.8), rapidperformance, and its ease of use, the luminescence based Kinase Glo® assay platform has gained wide acceptance in many drug screening programs for protein kinase inhibitors.

A Cell-Based, Microplate Format, DELFIA Assay for Determination of the Activation of MAP KinaseSofia

Oct 16

Mitogen-activated protein kinases(MAPK) are activated in response to extracellularsignals or cellular stress. We have set up a cell-based DELFIA®Time-Resolved Fluorescence assay to test compounds or conditions for their ability to modulate cellular stress by the activation of MAPK.

Cell Based Assays for Studying the Effects of Cytotoxic Agents

Oct 16

Apoptosis, DNA fragmentation and cell proliferation are important parameters when studying live cell function, especially, when the effects of cytotoxic agents are under study.

Evaluation of cadmium, lead, nickel and zinc status in biological samples of smokers and nonsmokers hypertensive patients

2 hours ago

The objective of this study was to evaluate the association between trace and toxic elements zinc (Zn), cadmium (Cd), nickel (Ni) and lead (Pb) in biological samples (scalp hair, blood and urine) of smoker and nonsmoker hypertensive patients (n=457), residents of Hyderabad, Pakistan. For the...

Angiotensin-converting enzyme gene and retinal arteriolar narrowing: The Funagata Study

2 hours ago

The purpose of this study is to determine whether the angiotensin-converting enzyme (ACE) gene polymorphism is associated with retinal arteriolar narrowing, a subclinical marker of chronic hypertension. The Funagata Study examined a population-based sample of Japanese aged 35+ years; 368...

EDITORIAL STATEMENT

2 hours ago

 

Request for Entries

Oct 16

Ask the Experts is your chance to get the answers to questions on applications, materials, methods, processes, and technologies. Email you question to bst_web@advantagemedia.com, and the editors of Bioscience Technology will find an appropriate expert to answer it. Watch this space in the future to see the questions your colleagues are posting.

STAY INFORMED: SUBSCRIBE TO

Magazine and E-mail Newsletters

Loading...
E-mail:   

MULTIMEDIA

Video:

Frontiers in Bioscience Learning and Memory Video

Oct 6

How does the brain learn and remember? An academic conference "Frontiers in Bioscience Learning and Memory" was held at City University of Hong Kong on June 16th.

Podcasts:

Allen Institute for Brain Research

Oct 14

Discussed in this interview are both the mouse brain project and the human cortex project with an emphasis on the importance of these projects to neuroscience research.